Results 71 to 80 of about 399,367 (396)

B cell mechanobiology in health and disease: emerging techniques and insights into therapeutic responses

FEBS Letters, EarlyView.
B cells sense external mechanical forces and convert them into biochemical signals through mechanotransduction. Understanding how malignant B cells respond to physical stimuli represents a groundbreaking area of research. This review examines the key mechano‐related molecules and pathways in B lymphocytes, highlights the most relevant techniques to ...
Marta Sampietro, Marco Cellani, Cristina Scielzo   +2 more
wiley   +1 more source

Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators [PDF]

, 2016
Residual disease in chronic myeloid leukemia (CML) patients undergoing therapy with tyrosine kinase inhibitors (TKIs) is measured by assessing the quantity of transcripts of the BCR-ABL1 fusion gene in peripheral white blood cells. This analysis is based
Bianchini, Michele, Cross, N. C. P., Larripa, Irene Beatriz, Medina, M., Mordoh, Jose, Ruiz, María Sol, Tapia, I.   +6 more
core   +1 more source

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2018
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene.
J. Radich, M. Deininger, C. Abboud, J. Altman, E. Berman, R. Bhatia, B. Bhatnagar, P. Curtin, D. DeAngelo, J. Gotlib, G. Hobbs, M. Jagasia, H. Kantarjian, L. Maness, L. Metheny, J. Moore, A. Pallera, Philip A. Pancari, M. Patnaik, E. Purev, M. Rose, N. Shah, B. Smith, D. Snyder, K. Sweet, M. Talpaz, James E. Thompson, David T Yang, K. Gregory, Hema M Sundar   +29 more
semanticscholar   +1 more source

Single‐cell insights into the role of T cells in B‐cell malignancies

FEBS Letters, EarlyView.
Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley   +1 more source

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

Haematologica, 2012
Background Protein phosphatase 2A is a novel potential therapeutic target in several types of chronic and acute leukemia, and its inhibition is a common event in acute myeloid leukemia.
Ion Cristóbal, Laura Garcia-Orti, Cristina Cirauqui, Xabier Cortes-Lavaud, María A. García-Sánchez, María J. Calasanz, María D. Odero   +6 more
doaj   +1 more source

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Leukemia, 2017
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-
A. Hochhaus, T. Masszi, F. Giles, J. Radich, D. Ross, M. T. G. Casares, A. Hellmann, J. Stentoft, E. Conneally, V. García‐Gutiérrez, N. Gattermann, W. Wiktor-Jedrzejczak, P. Coutre, B. Martino, Susanne Saussele, H. Menssen, W. Deng, N. Krunic, V. Bédoucha, G. Saglio   +19 more
semanticscholar   +1 more source

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

Haematologica, 2012
It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib.
Naoto Takahashi, Taiichi Kyo, Yasuhiro Maeda, Takashi Sugihara, Kensuke Usuki, Tatsuya Kawaguchi, Noriko Usui, Shinichiro Okamoto, Yokiko Ohe, Shigeki Ohtake, Kunio Kitamura, Masahide Yamamoto, Hirofumi Teshima, Toshiko Motoji, Toshiharu Tamaki, Kenichi Sawada, Kazuma Ohyashiki   +16 more
doaj   +1 more source

How I treat chronic myeloid leukemia in children and adolescents.

Blood, 2019
Evidence-based recommendations have been established for treatment of chronic myeloid leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this leukemia in children and adolescents makes it challenging to develop ...
N. Hijiya, M. Suttorp
semanticscholar   +1 more source

Rewriting the dendritic cell code in cancer—from subset identity to immunotherapeutic design

FEBS Letters, EarlyView.
Dendritic cells (DCs) play central roles in cancer immunity but are often subverted by the tumor microenvironment. This review explores the diversity of DC subsets, their functional plasticity, and emerging therapeutic strategies to reprogram DCs for enhanced antitumor responses, including vaccines, in vivo targeting, and DC‐based immunotherapies ...
Estevão Carlos Silva Barcelos, Doriana Ricciuti, Giada Mondanelli, Marco Gargaro   +3 more
wiley   +1 more source

A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients [PDF]

, 2017
Background: Protein tyrosine phosphatase receptor gamma (PTPRG) is a ubiquitously expressed member of the protein tyrosine phosphatase family known to act as a tumor suppressor gene in many different neoplasms with mechanisms of inactivation including ...
Al Sayab, Ali, Al-Dewik, Nader, Fiorini, Zeno, Holyoake, Tessa L., Ismail, Mohamed A., Krampera, Mauro, Lorenzetto, Erika, Mafficini, Andrea, Monne, Maria, Moratti, Elisabetta, Pellicano, Francesca, Sorio, Claudio, Tecchio, Cristina, Tomasello, Luisa, Vezzalini, Marzia, Yassin, Mohamed   +15 more
core   +3 more sources